Evotec SE (NASDAQ:EVO - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $3.60, but opened at $3.47. Evotec shares last traded at $3.51, with a volume of 2,517 shares.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a report on Thursday.
Check Out Our Latest Research Report on EVO
Evotec Trading Down 1.9 %
The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The business's 50-day moving average price is $3.65 and its two-hundred day moving average price is $4.08.
Institutional Investors Weigh In On Evotec
A number of hedge funds have recently modified their holdings of the business. Lighthouse Investment Partners LLC bought a new stake in Evotec during the 4th quarter worth approximately $166,000. DCF Advisers LLC raised its holdings in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after acquiring an additional 12,816 shares during the period. CSS LLC IL bought a new stake in Evotec in the 4th quarter valued at $50,000. Bank of America Corp DE lifted its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after acquiring an additional 9,289 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in Evotec in the 4th quarter worth $27,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
